PLAT and androgen insensitivity syndrome: Thrombolytic therapy with intravenous recombinant tissue plasminogen activator (IV rt‐PA) has been shown to improve functional outcomes and mortality risk at 90 days when administered within 4.5 h of symptom onset in patients with acute ischemic stroke (AIS) [4, 5], including in Asian and Chinese patients [6, 7, 8, 9, 10].